The rise of antibiotic-resistant bacterial pathogens is an increasingly global threat to public health, but non-antibiotic therapeutic drugs already approved for other purposes in people could be effective in fighting the antibiotic-resistant pathogens, according to a new study from researchers at The University of Texas Medical Branch (UTMB) at Galveston, Texas.
Antibiotic resistance is increasing due to over-prescription of antibiotics, said Ashok Chopra, a professor at UTMB and author of the new study published in the Journal of Antimicrobial Agents & Chemotherapy. The solution could lie with drugs originally meant for other uses that, until now, no one knew could also help combat bacterial infections.
While antibiotics have been highly effective at treating infectious diseases, infectious bacteria have adapted to them, and antibiotics have become less effective, according to the Centers for Disease Control & Prevention.
“There are no new antibiotics that are being developed, and nobody really has given much emphasis to this because everyone feels we have enough antibiotics in the market,” Chopra said. “Now, the problem is that bugs are becoming resistant to multiple antibiotics. That’s why we started thinking about looking at other molecules that could have some effect in killing such antibiotic-resistant bacteria.”
By screening a library of 780 Food & Drug Administration-approved therapeutics, Chopra, UTMB graduate student Jourdan Andersson and others on the research team were able to identify as many as 94 drugs that were significantly effective in a cell culture system when tested against Yersinia pestis, the bacteria that cause the plague and are becoming resistant to antibiotics.
After further screening, three drugs — the antipsychotic trifluoperazine, the breathing stimulant doxapram and the antidepressant amoxapine — were used in a mouse model and were found to be effective in treating plague. In further experiments, trifluoperazine was successfully used to treat Salmonella enterica and Clostridium difficile infections, both of which CDC lists as drug-resistant bacteria of serious threat.
“It is quite possible that these drugs are already unknowingly treating infections when prescribed for other reasons,” Chopra said.
Since they are not antibiotics, these drugs are not attacking the bacteria. Instead, they could be dealing with these bacteria in a couple of different ways, Chopra said.
The drugs could somehow be affecting the virulence of the bacteria — although in the case of plague, Chopra said the team found no evidence that the drugs were affecting the destructive strength of the plague-causing bacteria.
Another likely explanation is that the drugs are working through the host and could be affecting host proteins or genes in a way that the bacteria cannot use them to reproduce, Chopra said. There are still more studies needed to answer these and other questions, but Chopra said he is hopeful that this line of study could lead to a way to combat antibiotic-resistant bacteria.
“This area of antibiotic resistance is a big problem in global terms,” Chopra said. “That’s why we started thinking of what different ways we can use drugs already available to combat this problem.”